FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年5月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包 ...

Investment Rating - The report assigns an "Outperform" rating to the company for the first time, with a target price range of HKD 20.76 to 25.62, indicating a potential upside of 10.1% to 35.8% compared to the current stock price of HKD 18.86 [4][6]. Core Insights - The company is a leading player in the domestic medical imaging service sector, leveraging AI to enhance the value of imaging data. Despite facing revenue pressure in 2024, the long-term growth potential remains strong due to the expected expansion of third-party imaging services and the overall market growth [2][4][55]. - The company operates 106 imaging centers across 16 provinces in China, providing a comprehensive range of services that include imaging center services, imaging solution services, and cloud services [3][20][26]. - The medical imaging service market in China is projected to grow significantly, with a CAGR exceeding 30% from 2023 to 2030, driven by increasing demand and supportive policies for independent imaging centers [2][37]. Summary by Sections Financial Performance - In 2024, the company is expected to generate revenue of HKD 761 million, a decline of 18.1% year-on-year, with a net profit of -HKD 46 million, marking a shift from profit to loss [4][9][85]. - The gross margin for 2024 is projected at 36.5%, an increase of 0.7 percentage points, attributed to higher-margin differentiated imaging solutions and improved cost control [11][82]. Business Model and Strategy - The company has established a three-part service capability: imaging center services, imaging solution services, and cloud services, aiming to create a multi-layered, full-cycle medical imaging ecosystem [3][26][68]. - The company plans to expand its international business and has formed a joint venture to explore medical technology supply chain platforms [68][75]. Market Potential - The third-party medical imaging service market in China is still in its early stages, with a penetration rate of only about 1% as of 2023, compared to the more mature U.S. market [2][37][42]. - The report highlights the significant growth potential for third-party imaging centers, with the market expected to reach HKD 186 billion by 2030 [2][37]. Future Projections - Revenue forecasts for 2025 to 2027 are HKD 997 million, HKD 1.227 billion, and HKD 1.477 billion, respectively, with expected growth rates of 31.1%, 23.1%, and 20.3% [4][85]. - The company anticipates returning to profitability in 2025, with net profits projected at HKD 49 million, HKD 81 million, and HKD 113 million for the following years [4][85].

Group 1 - Company Yanguang Health Management is acquiring an 18.0% stake in Shanghai Ronggong Company from Fanghou No.1 [1] - The company will also subscribe for an additional 9.58% stake in Shanghai Ronggong through a capital increase agreement, with a total investment of RMB 12.72 million [1] - Following the completion of the capital increase, Yanguang Health Management will hold a total of 25.9% of Shanghai Ronggong [1] Group 2 - Yanguang Health Management is purchasing a 51.0% stake in Wuhan Ronggong for RMB 5.1 million, which will make Wuhan Ronggong a subsidiary of the company [2] - Shanghai Ronggong focuses on providing innovative financial technology solutions in the medical industry through its self-developed SaaS platform [2] - Wuhan Ronggong is involved in the wholesale and retail of various medical devices and has a significant market presence in the medical supply chain [2] Group 3 - The company aims to become a diversified imaging service provider for the entire medical imaging industry chain [3] - The strategic integration with Shanghai Ronggong and Wuhan Ronggong is expected to enhance the company's reach and create more business opportunities [3] - The acquisitions will enrich the company's financial tools and business models, promoting innovative solutions in imaging services [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 關連交易 (1) 訂立有關上海融公社的增資協議；及 (2) 自上海融公社收購武漢融公社51%股權 背景 茲提述本公司日期為2024年11月1日及2024年11月21日的公告，內容有關一脈陽 光健康管理（本公司一間全資附屬公司）向芳侯一號收購上海融公社18.0%的股權 的關連交易。 董事會欣然宣佈，於2025年5月23日（交易時段前），一脈陽光健康管理、上海 融公社、芳侯一號、芳侯投資、芳侯二號、武漢卓爾及彭盈松就一脈陽光健康 管理認購上海融公社9.58%的股權訂立增資協議。 背景 茲提述本公司日期為2024年11月1日及2024年11月21日的公告，內容有關一脈陽 光健康管理（本公司一間全資附屬公司）向芳侯一號收購上海融公社18.0%的股權 的關連 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 1 | 細則編號 | 修訂前 | 修訂後 | | --- | --- | --- | | 第六條 | 公司註冊資本：人民幣 | 公司註冊資本：人民幣 | | | 35,631.1832萬元。 | 35,631.1832萬元人民幣 | | | | 36,606.1832萬元。 | | 第二十條 | 公司的股份總數為 | 公司的股份總數為 | | | 356,311,832股，公司的股本 | 356,311,832366,061,832股， | | | 結構為：普通股356,311,832 | 公司的股本結構為：普通股 | | | 股。 | 356,311,832366,061,832股。 | | 第二百一十一條 | 本章程經公司股東會決議通過 | 本章程經公司股東會決議通過 | | | 之日起正式生效並施行。自本 | 自簽署之日起正式生效並施 | ...

Group 1: Company Performance - NetEase-S (09999) saw a significant increase of 10.89% in stock price after reporting Q1 2025 net revenue of RMB 28.8285 billion, a year-on-year increase of 7.4%, and gross profit of RMB 18.5 billion, up 8.6% [1] - H&H International Holdings (01112) rose over 8% as the market speculated on the ergotamine concept, with its Swisse brand showing strong performance in high-growth segments [2] - China Gold International (02099) experienced a stock price increase of over 5% after reporting a 351% rise in Q1 revenue to USD 273 million [2] Group 2: Clinical and Pharmaceutical Developments - Shandong Xinhua Pharmaceutical (00719) surged over 14% as COVID-19 infections showed an upward trend, with the company preparing for Phase II clinical trials of OAB-14 [1] - Innovent Biologics (01801) rose nearly 3% after announcing the completion of the first patient dosing in the Phase III clinical study of Ma Shidu peptide for obesity [1] - Kangxi Biologics (06185) increased over 3% after receiving approval from the Indonesian drug regulatory authority for its inhaled tuberculosis vaccine clinical trial [1] Group 3: Market Trends and Reactions - The Nasdaq Golden Dragon China Index fell over 2%, with notable declines in popular Chinese stocks such as Tiger Brokers (TIGR.US) down over 8% and Beike (BEKE.US) down over 5% [3] - UnitedHealth Group (UNH.US) experienced a significant drop of over 15% following reports of a U.S. Department of Justice investigation into potential insurance fraud [3] - Bitcoin-related stocks declined, with CleanSpark (CLSK.US) down nearly 6% and Coinbase (COIN.US) down over 7%, as Bitcoin itself fell over 1.5% [3]

江西一脈陽光集團股份有限公司 Jiangxi Rimag Group Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 有意根據一般授權於公開市場進行股份購回 本公告由江西一脈陽光集團股份有限公司（「本公司」）董事（「董事」）會（「董事 會」）自願作出。 董事會謹此宣佈，根據本公司股東（「股東」）於2025年4月23日舉行的本公司年度 股東會（「年度股東會」）上批准的購回H股的一般授權（「購回授權」），本公司有意 不時於公開市場購回本公司H股（「H股」），購回金額累計不超過1億港元（「股份購 回」）。根據購回授權，本公司獲准購回的H股最高數目為24,937,807股H股，佔年 度股東會日期已發行H股（不包括庫存股份）總數的10%。股份購回將由本公司的 內部資源提供資金。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 股東及潛在投資者務請注意，截至本公告日期，本公司並無購回任何H股。購回 任何H股將視乎 ...

FF305 公司名稱： 江西一脈陽光集團股份有限公司 呈交日期： 2025年5月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接於美國境內或有關刊發或派發屬違法的任何其他司法權 區刊發或派發。本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要 約。 本公告並不構成或組成於美國境內或有關發售屬違法的任何其他司法權區出售或購買或認購證 券的任何要約或招攬的一部分。本公告所述本公司股份並無亦不會根據1933年美國證券法（經 修訂）（「美國證券法」）登記，且不得於美國境內提呈發售或出售，惟根據美國證券法登記規定 進行登記者或獲豁免遵守該等登記規定者除外。本公司無意根據美國證券法登記本公告內所指 之任何證券，或在美國境內進行證券公開發售。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 完成根據一般授權配售新H股 整體協調人及配售代理 完成根據一般授權配售新H股 董事會欣然宣佈， ...

Group 1 - Company announced a placement agreement with agents including CITIC Securities, Guotai Junan International, and TradeGo Markets to facilitate the sale of 9.75 million shares at a price of HKD 20.00 per share [1] - The placement shares represent approximately 3.91% of the existing issued H shares and about 2.74% of the total issued shares as of the announcement date [1] - If all placement shares are fully subscribed, the total proceeds are expected to be approximately HKD 195 million, with a net amount of about HKD 182 million [2] Group 2 - The net proceeds from the placement will be allocated as follows: approximately 50% (HKD 91.15 million) for business investments and acquisitions, 25% (HKD 45.57 million) for overseas business expansion, 15% (HKD 27.34 million) for data and research, and 10% (HKD 18.23 million) for general working capital [2]